Integral Health Asset Management LLC Grows Position in Fresenius Medical Care AG (NYSE:FMS)

Integral Health Asset Management LLC increased its position in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 600,000 shares of the company's stock after purchasing an additional 150,000 shares during the quarter. Integral Health Asset Management LLC owned approximately 0.10% of Fresenius Medical Care worth $13,584,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in Fresenius Medical Care by 192.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock valued at $28,000 after buying an additional 806 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care in the 3rd quarter worth $38,000. Russell Investments Group Ltd. increased its holdings in shares of Fresenius Medical Care by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock worth $71,000 after purchasing an additional 2,208 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after purchasing an additional 2,012 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after purchasing an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

Shares of FMS opened at $28.37 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $28.59. The firm has a market capitalization of $16.65 billion, a P/E ratio of 23.45, a PEG ratio of 0.76 and a beta of 0.85. The business has a fifty day moving average of $24.55 and a 200 day moving average of $23.45.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The company had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. As a group, sell-side analysts anticipate that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Fresenius Medical Care Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be issued a $0.7871 dividend. The ex-dividend date is Friday, May 23rd. This represents a dividend yield of 1.9%. This is a positive change from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's payout ratio is presently 39.29%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.